阿扎那韦致胆红素升高:OATP1B1/3抑制可能比UGT1A1抑制更关键
阿扎那韦可使总胆红素升高至九倍,传统认为主要源于UGT1A1抑制,但UGT介导的相互作用通常不足两倍。该研究采用生理药代动力学(PBPK)分析整合体外与临床数据,定量评估UGT1A1与OATP1B1/3抑制对胆红素-阿扎那韦相互作用的贡献,提示UGT1A1抑制贡献不足33%,OATP1B1/3抑制可能是主要机制。
要点
- 阿扎那韦致胆红素升高不能仅用UGT1A1抑制解释。
- PBPK分析显示UGT1A1抑制贡献不足33%。
- OATP1B1/3抑制可能是胆红素升高的主要机制。
核心结论
- UGT1A1抑制在胆红素与阿扎那韦相互作用中作用有限,贡献不足33%,OATP1B1/3抑制可能是胆红素升高的主要原因。
- 非结合胆红素在UGT1A1抑制下不如雷特格韦敏感,可能不是UGT1A1抑制的有用内源性生物标志物。
研究设计与样本
- 采用生理药代动力学(PBPK)分析,整合多项相关体外与临床研究数据,定量评估UGT1A1和OATP1B1/3抑制对胆红素与阿扎那韦相互作用的贡献。
主要发现
- PBPK分析表明UGT1A1抑制对胆红素与阿扎那韦相互作用的贡献不足33%。
- 非结合胆红素对UGT1A1抑制的敏感性低于雷特格韦。
- 非结合胆红素的代谢与其他UGT酶介导的反应具有共同特征。
临床怎么用
- 临床解读阿扎那韦相关胆红素升高时,应同时考虑OATP1B1/3抑制,而非仅归因于UGT1A1抑制。
- 不宜将非结合胆红素作为评估UGT1A1抑制的可靠内源性生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atazanavir has been reported to increase total serum bilirubin level up to ninefold. It is widely believed that the observed total bilirubin elevation is primarily due to UGT1A1 inhibition. However, UGT enzymes are well-known as a low-affinity and high-capacity system, and the observed drug-drug interaction mediated by UGTs is usually less than twofold. There were discrepancies in the explanation of total bilirubin elevation due to UGT1A1 inhibition alone, suggesting the contribution of other mechanism(s) to the interaction. As atazanavir is a potent OATP1B1/3 inhibitor and the hepatic uptake of both unconjugated and conjugated bilirubin are mediated by OATP1B1/3, these transporters could be involved in the bilirubin-atazanavir interaction. To better understand the roles of UGT1A1 and OATP1B1/3 in this interaction, it would be useful to characterize the contribution of each individual pathway to the interaction. As multiple compounds, pathways, and potentially UGT1A1 polymorphism are involved, a thorough physiologically-based pharmacokinetic (PBPK) analysis was utilized to integrate the information from various relevant in vitro and clinical studies to quantitatively estimate the contribution of UGT1A1 and OATP1B1/3 inhibition to the interaction between bilirubin and atazanavir. The PBPK analysis indicated that UGT1A1 inhibition plays a modest role in bilirubin and atazanavir interaction contributing less than 33%. The results also suggested that unconjugated bilirubin is less sensitive than raltegravir upon UGT1A1 inhibition, therefore, unconjugated bilirubin may not be a useful endogenous biomarker for UGT1A1 inhibition. The analysis demonstrated that the metabolism of unconjugated bilirubin shares common features of other UGT enzyme-mediated reactions.
引用
- Dong J, Sharma P, Emara R, et al. Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration. Clin Pharmacol Ther. 2024. PMID: 39673699. doi:10.1002/cpt.3529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。